Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Conditions:   Advanced Carcinoid Tumor;   Advanced Neuroendocrine Neoplasm;   Atypical Carcinoid Tumor;   Locally Advanced Neuroendocrine Neoplasm;   Malignant Bronchial Neoplasm;   Metastatic Carcinoid Tumor;   Metastatic Neuroendocrine Neoplasm;   Unresectable Carcinoid Tumor;   Unr esectable Neuroendocrine Neoplasm Interventions:   Drug: Everolimus;   Drug: Lutetium Lu 177 Dotatate Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials